The Latest Cardiac and Vascular News
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and […]
Obtention of a €2.5m grant and potential equity investments of €15m PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that it has been […]
Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare […]
Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End Southlake, Texas, Dec. 16, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also […]
SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with […]
Follows recent equity financing, resulting in debt and equity gross proceeds of $15.2 million SILVER SPRING, Md., Dec. 15, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, […]
Top-tier investor syndicate includes new investors ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X, with follow on participation from existing investors including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne. […]
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (“Offeror”), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the “Offer”) to acquire all of the outstanding shares of […]
Strong environmental, social, and governance (ESG) management and performance result in continued inclusion on the Dow Jones Sustainability World Index DUBLIN, Dec. 14, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its continued inclusion in the Dow Jones® Sustainability World Index (DJSI) as one of the world’s leading […]
Acquisition expands the Maxwell Biomedical product and intellectual property portfolio. SAN DIEGO, Dec. 14, 2022 /PRNewswire/ — Maxwell Biomedical announced today that it has completed the acquisition of Cardialen’s assets. Cardialen, a Minneapolis, MN based company developed MultiPulse™ Therapy (MPT™), a low-energy defibrillation and cardioversion therapy designed to treat atrial fibrillation (AFib) and ventricular tachycardia […]
